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Abstract
Bovine viral diarrhoea (BVD) has been assessed according to the criteria of the Animal Health Law
(AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of BVD
to be listed, Article 9 for the categorisation of BVD according to disease prevention and control rules as
in Annex IV and Article 8 on the list of animal species related to BVD. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, BVD can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The
disease would comply with the criteria as in Sections 4 and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1).
The assessment here performed on compliance with the criteria as in Section 3 of Annex IV referred to
in point (c) of Article 9(1) is inconclusive. The animal species to be listed for BVD according to Article 8
(3) criteria are mainly species of the families Bovidae, Cervidae and Camelidae as susceptible species
and several mammalian species as reservoirs.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on bovine viral diarrhoea (BVD) according
to the criteria of the AHL articles as follows:
• Article 7: BVD proﬁle and impacts
• Article 5: eligibility of BVD to be listed
• Article 9: categorisation of BVD according to disease prevention and control rules as in Annex IV
• Article 8: list of animal species related to BVD.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of BVD according to the Article 7 criteria of the AHL and related
parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on the
information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1 of the
scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel. Bovine viral diarrhoea
virus (BVDV) is a member of the Pestivirus genus of the family Flaviviridae.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Evidence for natural susceptibility of wildlife species (Passler and Walz, 2010; Ridpath and Neill,
2016) comes mainly from serological surveys. While these have typically demonstrated the presence of
antibodies capable of neutralising BVDV, the possibility that they may in some cases indicate exposure
to a different, but related, Pestivirus cannot be excluded. Those species from which BVDV has been
isolated (or viral antigen/RNA detected), conﬁrming their susceptibility are underlined below; otherwise
natural susceptibility is based on serological evidence. Where only serological evidence of infection
exists, it is recognised that due to the cross-reactive nature of pestiviral antibodies it is possible that
these are due to infection with other pestiviral species and do not provide deﬁnitive evidence of
susceptibility to BVDV (Ridpath and Neill, 2016).
Order Artiodactyla
Family Bovidae
African Buffalo (Syncerus caffer)
American Bison (Bison bison) (Ridpath and Neill, 2016)
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Bighorn Sheep (Ovis canadensis) (Ridpath and Neill, 2016)
Blue Wildebeest (Connochaetes taurinus)
Bushbuck (Tragelaphus scriptus)
Chamois (Rupicapra pyrenaica pyrenaica) (Ridpath and Neill, 2016)
Defrassa Waterbuck (Kobus ellipsiprymnus)
Duiker (Sylvicapra grimmia)
Eland (Taurotragus oryx) (Passler and Walz, 2010)
European Bison (Bison bonasus)
Gemsbok (or Oryx) (Oryx gazella)
Hartebeest (Alcelaphus buselaphus)
Impala (Aepyceros melampus)
Kudu (Tragelaphus strepsiceros)
Lechwe (Kobus leche)
Lichenstein’s Hartebeest (Alcelaphus lichtensteinii)
Mouﬂon (Ovis orientalis)
Mountain goat (Oreamnos americanus) (Ridpath and Neill, 2016)
Nilgai (Boselaphus tragocamelus) (Passler and Walz, 2010)
Nyala (Tragelaphus angasi)
Oryx (Oryx gazelle)
Reedbuck (Redunca arundinum)
Roan Antelope (Hippotragus equinus)
Sable Antelope (Hippotragus niger)
Springbok (Antidorcas marsupialis)
Topi (Damaliscus lunatus jimela)
Tsessebe (Damaliscus lunatus)
Waterbuck (Kobus ellipsiprymnus)
Wildebeest (Connochaetes taurinus)
Family Cervidae
Axis Deer (Axis axis) (Passler and Walz, 2010)
Barasingha Deer (Cervus duvaucelii) (Passler and Walz, 2010)
Caribou (Rangifer tarandus caribou)
Chinese Water Deer (Hydropotes inermis) (Ridpath and Neill, 2016)
Elk (Cervus canadensis)
Fallow Deer (Dama dama)
Grey Brocket Deer (Mazama gouazoubira)
Moose (Alces alces)
Mule Deer (Odocoileus hemionus) (Ridpath and Neill, 2016)
Pampas Deer (Ozotoceros bezoarticus celer)
Red Deer (Cervus elephus) (Ridpath and Neill, 2016)
Reindeer (Rangifer tarandus)
Roe Deer (Capreolus capreolus) (Ridpath and Neill, 2016)
Sika Deer (Cervus nippon)
White-Tailed Deer (Odocoileus virginianus) (Ridpath and Neill, 2016)
Family Girafﬁdae
Giraffe (Giraffa camelopardalis) (Ridpath and Neill, 2016)
Family Antilocapridae
Pronghorn (Artilocapra americana) (Ridpath and Neill, 2016)
Family Camelidae
Alpaca (Vicugna pacos) (Passler and Walz, 2010)
Dromedary (Camelus dromedarius) (Passler and Walz, 2010)
Guanaco (Lama guanicoe)
Llama (Lama glama) (Passler and Walz, 2010)
Vicuna (Vicugna vicugna)
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Family Suidae
Wart Hog (Phacochoerus africanus)
Wild Boar (Sus scrofa) (Ridpath and Neill, 2016)
Family Traguilidae
Mousedeer (Tragulus javanicus) (Grondahl et al., 2003)
Order Lagomorpha
Evidence of susceptibility of Leporidae (order Lagomorpha) has been published. A study in wild
rabbits in Germany found low levels of neutralising antibodies in 40/100 sera (Fr€olich and Streich,
1998), although attempts at virus isolation were unsuccessful. A survey in the UK reported a weak
positive result by enzyme-linked immunosorbent assay (ELISA) (and with high levels of non-speciﬁc
binding) in 3/260 wild rabbits (Grant et al., 2015), with the authors concluding BVDV is not established
as an endemic infection of rabbits in the regions of the UK where sampling was conducted (Bachofen
et al., 2014; Grant et al., 2015). More recently, 34/94 sera from European hares were found to contain
virus neutralisation (VN) antibodies to a ruminant pestiviruses (Colom-Cadena et al., 2016) with none
testing positive for viral RNA by real time RT-PCR.
Family Leporidae
Rabbit (Oryctolagus cuniculus) (Fr€olich and Streich, 1998; Grant et al., 2015)
European hare (Lepus europaeus) (Colom-Cadena et al., 2016)
Parameter 2 – Naturally susceptible domestic species (or family/orders)
BVDV is predominantly a pathogen of cattle, but interspecies transmission can occur following
contact with sheep, goats and pigs. In common with cattle, infection of sheep can result in the birth of
viable persistently infected (PI) lambs. In contrast, the birth of PI offspring appears to be a rare result
of in utero infection in goats and pigs (Passler and Walz, 2010).
Order Artiodactyla
Family Bovidae
Cattle
Sheep
Goats
Family Suidae (Pigs)
Pigs
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Family Leporidae
Rabbit (Oryctolagus cuniculus)
Challenge of New Zealand White rabbits with BVDV by the intravenous (IV) and oronasal (ON)
routes, and via contaminated hay resulted in seroconversion in some or all rabbits in each group in the
absence of clinically apparent disease (Bachofen et al., 2014). All whole blood samples collected from
each group during serial bleeds were negative by real time RT-PCR, as were oral swabs (providing no
evidence for shedding by this route). Tissue samples and buffy coat were collected from rabbits
challenged by the IV and ON routes, with some positive results, particularly following IV challenge.
Virus isolation was attempted on ileum collected following IV challenge, with positive results.
IV challenge of pregnant rabbits did not result in clinical signs or increased rates of abortion or
stillbirth (Grant et al., 2015). Relatively few offspring (21%) had evidence of infection by real time
RT-PCR at the end of the experiment (maximum 10 days of age), with a proportion of these also
seropositive by ELISA. Persistence of infection was therefore not demonstrated.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
With the exception of rabbits mentioned under Parameter 3 a range of non-arteriodactyls, including
horses, cats, dogs, guinea pigs, mice and embryonated chicken eggs have previously been reported not
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to be susceptible to infection with BVDV (Baker et al., 1954), although recent work has suggested that
mice can be infected when inoculated by oral and intra-nasal challenge (Seong et al., 2015, 2016).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
Lack of strict host species speciﬁcity raises the possibility of reservoir species, but it has been
considered that natural infections in species other than cattle and sheep do not represent a disease
problem for control programmes in domestic ruminants (Løken and Nyberg, 2013). Passler et al.
(2016) propose four criteria that a potential wildlife reservoir must satisfy: (1) be susceptible to BVDV,
(2) shed BVD (particularly through persistently infected animals), (3) maintain BVDV in the population,
(4) have sufﬁcient contact with cattle to allow spillback infections to occur. Applying these criteria to
white-tailed deer (Odocoileus virginiansis) in the US, where they have been intensively studied in
relation to BVDV, they conclude that they represent a low risk as an important reservoir species in
most environments. In general, seroprevalence levels are much lower in wildlife (Passler and Walz,
2010) than in cattle in endemic situations, suggesting that the former are spillover hosts rather than
true reservoir species. Evermann (2006) suggests three proposed population groups for pestiviral
infections: cervid, camelid and domestic ruminants, with pestiviruses (which may be distinct from
BVDV) circulating within and, under optimum conditions, between these clusters. While this may result
in disease, the potential for limited intrahost spread in the new population is suggested to limit the
possibility of this leading to an epidemic in the new population.
In Europe, a number of studies have also investigated the seroprevalence of BVDV in deer, typically
to examine their epidemiological importance in the context of national eradication programmes. A
serosurvey of free-living deer from regions of Denmark with a relatively high prevalence of cattle herds
with a persistent BVD infection status prior to its eradication from cattle found a very low prevalence
of cervid infection (Nielsen et al., 2000). The authors concluded that the positive animals were likely to
have resulted from transmission from cattle to deer and that transmission among deer or from deer to
cattle was highly unlikely and therefore that the possibility of free-living deer being a source of
infection for cattle was remote.
A serological survey in Norway between 1993 and 2000 found 12.3% roe deer to be seropositive to
BVDV, with the authors concluding that pestivirus is endemic in this species (Lillehaug et al., 2003).
While they noted the possibility of deer to cattle transmission impacting on eradication and surveillance
within the Norwegian eradication programme, this has proven unfounded as demonstrated by the
successful completion of the eradication programme (Løken and Nyberg, 2013).
The role of wild ruminants, including red and roe deer, in the epidemiology of BVDV infections in
domestic livestock in Switzerland was investigated (Casaubon et al., 2012). The authors found that
despite regular interactions with farmed ruminants, infection in wild ruminants was sporadic with VN
antibodies not found in any of 435 roe deer and detected in only 13/476 red deer (2.7%). They
concluded that wildlife was an incidental spillover host rather than a reservoir host for BVDV and as
such did not represent a threat to the Swiss national BVDV eradication programme in livestock (Presi
and Heim, 2010).
A recent study in Belgium (Tavernier et al., 2015) of wild roe deer found only 1.3% seropositive,
despite an expanding population and regular contact with livestock, concluding that they do not play
an important role in the epidemiology of infection in domestic animals.
A similar study was conducted in the south of Spain (Paniagua et al., 2016) where wild ruminant
populations have also increased substantially, resulting in the frequent sharing of habitats with
domestic livestock. It found only 1 of 892 red deer to be seropositive and concluded that the deer
were spillover hosts only and did not represent a risk for domestic ruminants. Another study of
sympatric alpine populations of livestock and wild ruminants, including deer in north-west Spain
generated similar ﬁndings (Fernandez-Aguilar et al., 2016).
Grant and others (Grant et al., 2015) consider that a wildlife reservoir in the rabbit
(Oryctolagus cuniculus) poses a small but non-zero risk of re-infection for BVDV-free cattle herds.
While this is unlikely to be of epidemiological relevance for most control scenarios, it may theoretically
play a role in the tail end of an eradication campaign.
Detection of VN antibodies to pestiviruses, including BVDV, in European hares (Lepus europaeus)
has led to the suggestion that they may be a wildlife reservoir, particularly in relation to the Pyrenean
chamois (Colom-Cadena et al., 2016).
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Parameter 6 – Domestic reservoir species (or family/orders)
Sheep and goats are susceptible to infection with BVDV. While both sheep and goats PI with BVDV
have been described, foetal death and non-viability of lambs are common sequelae of transplacental
infection in sheep and viable PI kids are considered a rare result of in utero infection in goats, where
reproductive failure or gross pathology of infected foetuses are the likely outcome (Løken, 1995; Bitsch
et al., 2000; Krametter-Froetscher et al., 2010; Passler and Walz, 2010).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
A series of investigations aimed at assessing the prevalence of BVDV infection have been
performed in Europe, from the late seventies and into the 21st century, and the results of these at
both animal- (Table 1) and herd-levels (Table 2) have been reviewed within the position paper
published by the EU Thematic network on control of bovine viral diarrhoea virus (BVDV) (2001).
The general picture is that in many European countries without systematic control in place, or
before such measures were implemented, the infection has been/is endemic at a high level with
60–80% of the animals being antibody positive and 1–2% being persistently infected. In many
countries, surveys indicated that almost all herds had antibody carriers and approximately half of them
had PI animals. However, a few countries had quite a different picture with much lower prevalences.
This heterogeneity in the presence of BVDV infection in the absence of systematic control was
considered likely to be a reﬂection of the distribution of risk factors for new BVDV infections and for
persistence of the infection in the respective countries.
Where a systematic approach has been adopted in MS, signiﬁcant progress has been made. The
Scandinavian Member States (MS) Sweden, Finland, Denmark have completed eradication programmes
(as has Norway) (Stahl and Alenius, 2012; Løken and Nyberg, 2013; Foddai et al., 2014; Norstr€om
et al., 2014; Finnish Food Safety Authority Evira, 2016), while national or regional programmes are
under way and have reduced the prevalence of PI births in a number of other MS, including Austria,
Germany, Ireland, Scotland and Belgium (Rossmanith et al., 2010; Schirrmeier et al., 2012; Clegg
et al., 2016; Duncan et al., 2016; Ribbens et al., 2016) and in Switzerland (Presi et al., 2011).
AHL assessment on bovine viral diarrhoea (BVD)
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2017;15(8):4952
Table 1: Animal-level prevalence of BVDV (seropositivity and persistent infection) in EU member states (reproduced from Table 6 of the EU Thematic
network on control of bovine viral diarrhoea virus (BVDV) (2001))
Country/
Region
Study
Period
Sampling
Frame
Sampling Method Sample Size Prevalence (AB) Prevalence (Virus)
Vaccination Reference
Herds Animals Herds Animals
Herd
level
number
(%)
Animal level
number (%)
Herd
level
number
(%)
Animal
level
number
(%)
Belgium . . . S. Belgium,
Belgium White
Blue and
Friesian
Holstein
Some herds
suspicious or
had poor
diagnosis
(42.5%)
All animals
in herd
61 9,685 61 (100) 6,344 (65.5) 27 (44.3) 73 (0.75) Some
vaccination
(not
considered
important)
Schreiber
et al.
(1999)
Belgium 2009–2010 A cross-
sectional study
Random Between 6
and 12
months
773 5,246 47.4 32.9 4.4 0.3 Some
vaccination
Sarrazin
et al.
(2013)
Denmark 1988 Jutland in
Denmark;
Dairy herds
Representative
NPE
All per farm 19 2,570 19 (100) 1,655 (64.4) 10 (52.6) 35/28
(1.4/1.1)
No
Vaccination
Houe and
Meyling
(1991)
Germany . . . N. Germany.
Breeding
animals
Exporting
herds
Pregnant
NPE
˃ 1,000 2,317 – – – 21 (0.9
[viraemic])
. . . Liess et al.
(1987)
Germany 1993–1994 Lower Saxony NPE Up to
3 years
329 20,253 – – 149
(45.3)
425 (2.1) Some
vaccination
Frey et al.
(1996)
Hungary 2008–2012 Country wide,
voluntary herd
screening for
BVDV or animal
trade
Country wide,
voluntary herd
screening for
BVDV or animal
trade
Up to
2 years
3,247 570,524 12.4 Within
herd:
7.2%,
0.89% for
all animals
in all herds
Szabara
et al.
(2016)
Ireland 2009 Cross-sectional
study of a
stratiﬁed
random sample
of 1,171 Irish
dairy and beef
cow herds
Randomly
constructed
within-herd
serum pools
1,171 98.7 Not
vaccinated
herds
Cowley
et al.
(2012)
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Country/
Region
Study
Period
Sampling
Frame
Sampling Method Sample Size Prevalence (AB) Prevalence (Virus)
Vaccination Reference
Herds Animals Herds Animals
Herd
level
number
(%)
Animal level
number (%)
Herd
level
number
(%)
Animal
level
number
(%)
Lithuania 1997–2001 27 regions Some suspect
herds
Some
suspect
herds
147 3,798 103
(70.1)**
2,211 (58.2) – – No
Vaccination
(Mockeliunas
et al.,
2004)
The
Netherlands
. . . 9 herds
participating in
BHV1
vaccination
trial. ˃ 100
involved in
international
trade
– Random ˃ 100 1,798 – 1,169 (65) – – . . . (Kramps
et al.,
1999)
Norway 1984–1986 Wide
geographic
representation.
Norwegian
Red cattle
Representative
NPE
Random,
˃ 2 years
187 1,133 52 (28) 210 (18.5) – – No
Vaccination
(Løken
et al.,
1991)
Poland . . . Bulls at
artiﬁcial
insemination
centres
– ˃ 6 months
old
– 175 – 150 (86) – – . . . (Polak and
Zmudzinski,
1999)
Poland . . . Bulls at
artiﬁcial
insemination
centres
– ˃ 6 months
old
– 219 – – – 5/2
(2.3/0.9)
. . . (Polak and
Zmudzinski,
1999)
Poland Publication
year 2015
Young beef
Cattle on the
farms
examined in
south-eastern
Poland
Between 6
and
12 months
old
15 78 6.41 3.85 Animals not
vaccinated
Wernicki
et al.
(2015)
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Country/
Region
Study
Period
Sampling
Frame
Sampling Method Sample Size Prevalence (AB) Prevalence (Virus)
Vaccination Reference
Herds Animals Herds Animals
Herd
level
number
(%)
Animal level
number (%)
Herd
level
number
(%)
Animal
level
number
(%)
Poland 2008–2011 Sampling in
the frame of
monitoring of
classical swine
fever
14,608 0.31 Lipowski
(2014)
Scotland 1992–1993 S.W. Scotland
breeding bulls
on dairy, beef
or mixed farms
(5 bulls from
dealers)
– Random 78 109 – 85 (78) – – . . . McGowan
and Murray
(1999)
Slovakia 2000 6–12 months
old
. . . Random 45 1,295 . . . 894 (69.0) – – Animals not
vaccinated
Vilcek et al.
(2003)
Slovakia 2000 6–12 months
old
Herds with 70–
98%
seropositivity
Random 13 462*** – – . . . 6 (1.3) Animals not
vaccinated
Vilcek et al.
(2003)
Slovenia 1996 5 regions
breeding herds
– All animals
in herd
274 6,892 – 1,144 – – . . . Grom and
Barlic-
Maganja
(1999)
Spain 1997 Asturias region.
Dairy herds
Random/
stratiﬁed NPE
˃ 1 year
old. 20
herds; all
animals. 8
herds;
random
28 529 24 (86) 112 (21.1
[CI: 17.8-
24.6])
– – No
vaccination
Mainar-
Jaime et al.
(2001)
Spain 2010–2014 Area of
chamois in the
Cantabrian
Mountains,
north-Western
Spain
Sera samples
from hunted
wild life
Chamois:
78
Red deer:
65
Roe deer:
24
Chamois: 0
Red deer:
10.8
Roe deer: 0
Animals not
vaccinated
Fernandez-
Aguilar et al.
(2016)
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Country/
Region
Study
Period
Sampling
Frame
Sampling Method Sample Size Prevalence (AB) Prevalence (Virus)
Vaccination Reference
Herds Animals Herds Animals
Herd
level
number
(%)
Animal level
number (%)
Herd
level
number
(%)
Animal
level
number
(%)
Spain 2010–2014 Area of
chamois in the
Cantabrian
Mountains,
north-Western
Spain
Sera samples
from cattle,
sheep and
goats
10 animals
per herd
Cattle: 13
Sheep: 8
Goats: 4
Cattle: 133
Sheep:
102
Goats: 37
Cattle: 100
Sheep: 25
Goats: 0
Cattle: 59.4
Sheep: 5.9
Goats: 0
Animals not
vaccinated
Fernandez-
Aguilar et al.
(2016)
Sweden 1987 County of
Kopparberg.
Dairy herds
Random All lactating
cows
15 413 11 (73) 190 (46) – – No
Vaccination
Niskanen
et al.
(1991)
Switzerland 1994–1995 Canton of St
Gallen
Random Cows and
heifers (all)
95 2,892 95 2,421 – – . . . Braun
et al.
(1997)
Switzerland 1995 Canton of St
Gallen, 7
Alpine
pastures. Swiss
Braunvieh
cattle. Dairy
herds
Invited by
cantonal
veterinary
ofﬁcer
Animals
prior to
pasture;
98% were
replacement
cattle. NPE
149 990 – 627 (63.3) – 9 (0.9) . . . Braun
et al.
(1998)
Switzerland 1993–1994 Dairy herds Random (at
least 5 cows)
All cows 113 1,635 112 (99.1) 1,174 (72) – – . . . St€ark et al.
(1997)
United
Kingdom
1974–1975 England and
Wales
3 herds in each
country
12 per herd
representing
a range of
ages
133 1,593 – 988 (62) – – . . . Harkness
et al.
(1978)
United
Kingdom
1980–1985 . . . . . . Beef calves
2–4 months
old. Cows 2
–3 year old.
Gnotobiotic
calves. NPE
– 924 – – – 7/4
(0.8/0.4*)
. . . Howard
et al.
(1987)
AHL assessment on bovine viral diarrhoea (BVD)
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2017;15(8):4952
Country/
Region
Study
Period
Sampling
Frame
Sampling Method Sample Size Prevalence (AB) Prevalence (Virus)
Vaccination Reference
Herds Animals Herds Animals
Herd
level
number
(%)
Animal level
number (%)
Herd
level
number
(%)
Animal
level
number
(%)
United
Kingdom
1985–1986 England and
Wales
– Submissions
of ˃ 10
samples to
CVL
– 18,759 – 12,175
(64.9)
– – . . . Edwards
et al.
(1987)
United
Kingdom
1986 Central
Veterinary
Laboratory
– Submissions
of ˃ 10
samples to
CVL
– 3,151 – – – 57 (1.8
viraemic)
. . . Cornish
et al.
(2016)
United
Kingdom
2006–2007 Scotland Stratiﬁed
random
sampling
design based
on agricultural
census data
301 16 Around 25%
vaccination
Br€ulisauer
et al.
(2010)
Note: Some numbers may have been calculated from percentages given in publications.
General legends and abbreviations in tables:
–: Information not measured or applicable.
. . .: Information not available in the paper.
NPE: no past evidence, meaning that herds were not selected based on past evidence of infection (unknown BVD status).
AI: artiﬁcial insemination centres.
BHV: Bovine herpes virus.
*: First number: Viraemic; Second number: Known to be PI.
**: Not all animals in each herd are tested (i.e. herd prevalence is underestimated).
***: Only 84 antibody negative tested.
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Acute (transient) infections: The case-morbidity rate for acute (transient) infections varies with a
range of factors, including the age of the animal, its immune status and its reproductive state (Lanyon
et al., 2014). The majority of acute infections are considered subclinical. However, infection of a BVDV
na€ıve animal results in a transient viraemia which can be associated with short-term leukopenia,
lymphopenia and/or thrombocytopenia, apoptosis in the thymus, and pyrexia. The resultant
immunosuppression, particularly in calves, can allow other infectious agents to become established, or
allow the recrudescence of existing infections resulting in enteric or respiratory disease.
Infection of na€ıve breeding animals may have a range of negative outcomes depending on the
stage of reproduction, including fertilisation failure, early embryonic death, abortion, congenital defects
and the birth of PI offspring which may be weak, undersized and ill-thrifty. Acute infection of sexually
active bulls results in a reduction in sperm density and motility, plus an increase in sperm abnormalities
(Lanyon et al., 2014).
Following the emergence of BVDV II in North America, much higher case morbidity rates (and
mortality rates) were reported (Carman et al., 1998). The within-herd abortion rate was 44%
(3–83%). The mortality rate was 53% (3–83%) for animals under 2 years of age and 9% (2–26%) for
older animals. A recent study of BVDV type 2c in Germany reported a case-fatality rate of up to 60%
and mortality in outbreak farms varied between 2.3% and 29.5% (Gethmann et al., 2015).
Table 2: Herd-level prevalence of BVDV (seropositivity and persistent infection) in EU member
states (reproduced from Table 7 of the EU Thematic network on control of bovine viral
diarrhoea virus (BVDV) (2001))
Country/
Region
Study
Period
Sampling
Frame
Sampling
method
Sample
size
(Herds)
Sample
Herd
prevalence
AB* Number
(%)
Herd
prevalence
Virus/act.
Inf Number
(%)
Vaccination Reference
Austria 1996–
1998
Nieder-
Osterreich.
All
breeding
herds
Stepwise:
A; milk, B;
Spot test,
and C; All
animals
NPE
A: 5,024
B: 512
C: 154
Milk
Spot test
All
animals
– 50 (1.0)
(PI animals
were
identiﬁed)
. . . Rossmanith
and Deinhofer
(1998)
Denmark 1994 Dairy
herds
All herds 16,113 Bulk milk – 6,284 (39)
(suspected
to have PI)
No
vaccination
Bitsch and
Rønsholt
(1995)
Estonia 1993–
1995
1997–
1998
1999–
2000
Dairy cows
with ≥ 20
cows
Random
sample
328
363
351
Bulk milk
and/or
young
stock test
152 (46)
65 (18)
(suspected
to have PI)
No
vaccination
Viltrop et al.
(2002)
Finland 1993 Dairy
herds
All herds
(˃ 98%)
34,115 Bulk milk 342 (1) – No
vaccination
Nuotio et al.
(1999)
England
and
Wales
1996 9 regions.
Dairy
herds ˃ 40
cows
Systematic
random
sample
1,070 Bulk milk 1,021 (95.4) 701 (65.5) No
vaccination
Paton et al.
(1998)
Northern
Ireland
1999 Dairy
herds
From the
largest
milk
processor
929 Bulk milk 920 (99)
(OD ˃ 0.04)
461 (49.6)
(OD ˃= 0.55)
. . . Graham et al.
(2001)
Norway 1993 Dairy
herds
All herds 26,430 Bulk milk 9,779 (37)
(OD ˃ 0.05)
1,877 (7.1)
(OD ˃ 0.55)
No
vaccination
Waage et al.
(1996)
Sweden 1993 Dairy
herds
Majority of
dairy herds
14,463 Bulk milk – 7,376 (51%)
(OD ˃ 0.55)
No
vaccination
Alenius et al.
(1997)
*: Note that the antibody detection methods vary between countries as do the cut offs when a herd is considered to have
antibody carriers or PI animals. Prevalences are therefore just indicative of the level and not directly comparable between
countries.
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Persistent infections: PI animals have been shown to be signiﬁcantly smaller than non-PI animals
(Table 3). The annual incidence risk of dying or being slaughtered due to unthriftiness was calculated
as 0.28 and 0.31 among 34 PI animals in 10 Danish dairy herds (Houe, 1993).
Observational studies on the impact of infection with BVDV on health and production parameters
have been reviewed in the EU Thematic network on control of BVDV (2001) and the results are
reproduced below (Table 3).
Table 3: Health and production effects of BVDV under different production settings in Europe
(observational studies) (reproduced from Table 5 of the EU Thematic network on control
of bovine viral diarrhoea virus (BVDV) (2001))
Country/
region
Outcome variable
BVD condition
(risk or
exposure
factor)
Measure
Number of
animals/
herd
Size of
measure
Reference
Netherlands Reduced milk yield
with ˃ 10%
Seroconversion
vs no
seroconversion
OR 22
seroconverted
32 not
seroconverted
11.5 (CI 3.0–
43.5) for more
than 10%
reduction in milk
yield
Moerman
et al.
(1994)
Netherlands Moderate or severe
bronchopneumonia
Receiving
colostrum from
AB negative
dams (A) vs. AB
positive dams
(B)
Incidence
risk
AB-neg
colostrum:
44 calves
AB-pos
colostrum:
86 calves
A: 68.2%
developed
symptoms
B: 40.7%
developed
symptoms
Moerman
et al.
(1994)
Sweden Heart girth PI calves vs.
non-PI calves
Cm at
80 days
Cm at 180
days
8 PI
13 non-PI
80 days: PI:
96.3 4.7 cm;
non-PI: 100.5
2.3 cm
PI: 123.3
8.8 cm;
non-PI: 130.2 
2.0 cm
Larsson
et al.
(1994)
Sweden Mastitis Recent herd
infection
compared to low
level of A in bulk
ilk
OR 91 herds
(7 with recent
inf. And 84
without inf.)
1.8 (CI: 1.7–2.8) Niskanen
et al.
(1995)
Sweden Miscellaneous
diseases
Recent herd
infection
compared to low
level of A in bulk
ilk
OR 91 herds
(7 with recent
inf. And 84
without inf.)
2.8 (CI: 1.7–4.4) Niskanen
et al.
(1995)
Sweden Retained placenta Recent herd
infection
compared to low
level of A in bulk
ilk
OR 91 herds
(7 with recent
inf. And 84
without inf.)
2.8 (CI: 1.6–4.7) Niskanen
et al.
(1995)
Sweden Oestrus stimulating
treatment
Long-term herd
infection
compared to low
level of AB in
bulk milk
OR 142 herds
(58 with inf.
and 84
without)
1.8 (CI: 1.3–2.6) Niskanen
et al.
(1995)
Sweden Calving interval Long-term herd
infection
compared to low
level of AB in
bulk milk
Days 142 herds
(58 with inf.
and 84
without)
Long-term inf.:
394 (389–398)
Non-infected:
385 (381–389)
Niskanen
et al.
(1995)
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Mortality
Parameter 3 – Case-fatality rate (Table 4)
Country/
region
Outcome variable
BVD condition
(risk or
exposure
factor)
Measure
Number of
animals/
herd
Size of
measure
Reference
Sweden Average annual milk
yield per cow
Herds with
detection of
virus vs free
herds
kg ECM 319 case
herds
2,270 control
herds
Interaction with
herd size:
30 cows:
142 kg (CI:
281 to 3)
less in case
herds
40 cows:
198 kg (CI:
330 to 66)
50 cows:
254 kg (389
to 119)
Lindberg
and
Emanuelson
(1997)
Sweden Average bulk milk
somatic cell count 9
1,000
Herds with
detection of
virus vs free
herds
cells/mL 319 case
herds
2,270 control
herds
10,300 (1,600–
18,900) cells/mL
more in case
herds
Lindberg
and
Emanuelson
(1997)
Norway Clinical mastitis Herds with rise
in bulk milk
antibodies vs
herds with
continuous low
level
Incidence
rate
300 exposed
herds vs
13,671
non-exposed
7.1% (CI: 0.2–
11.4) increase in
exposed herds
Waage
(2000)
Switzerland Fetal death (mid-
term abortion)
Seroconversion
vs no
seroconversion
OR and
PAF
62 cases
952 controls
3.10 (CI: 1.16–
8.29), PAF 7%
(CI: 2.4–14)
R€ufenacht
et al.
(2001)
France Late return to
service (after
25 days)
Past-infected-
recently
recovered vs Not
recently infected
RR 150,854 AI
122,697 cows
6,149 herds
1.03 (CI: 1.01–
1.05)
Robert
et al.
(2004)
France Late return to
service (after
25 days)
Past steadily
infected vs. Not
recently infected
RR 150,854 AI
122,697 cows
6,149 herds
1.11 (CI: 1.05–
1.17)
Robert
et al.
(2004)
France Late return to
service (after
25 days)
Recently infected
vs Not recently
infected
RR 150,854 AI
122,697 cows
6,149 herds
1.11 (CI: 1.02–
1.22)
Robert
et al.
(2004)
Holland Prevalence of
animals with clinical
signs
Transient
infection
% 136 cattle (1
herd)
7 of all animals
with transient
infection showed
clinical signs
(5%)
Moerman
et al.
(1994)
Table 4: Case-fatality rate for different types of infection (data extracted from Lanyon et al. (2014))
Case-fatality rate
Mucosal disease 100%
Persistently infected animal High
Transiently infected animal Low (but may be increased by secondary infections due to BVDV-
induced immunosuppression)
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
BVDV is not considered zoonotic, although the ability of BVDV to replicate in human cell lines has
been reported in some studies and there are limited reports of detection of virus, viral RNA or antigen
in human samples (Giangaspero et al., 1997; Walz et al., 2010; Bratcher et al., 2012).
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
Not applicable to viruses.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
Transiently infected (TI) animals: 0–14 days (Niskanen et al., 2002; Lindberg and Houe, 2005;
Nickell et al., 2011; Sarrazin et al., 2014).
Persistently infected animals: lifelong (Lindberg and Houe, 2005).
Parameter 2 – Presence and duration of latent infection period
True latency is not described for BVDV.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Persistent infected animals may be apparently normal and healthy or small, weak and ill-thrifty:
they are lifelong carriers and shedders of BVDV (Lindberg and Houe, 2005; Lanyon et al., 2014).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
In general, pestiviruses including BVDV have limited ability to maintain their infectivity outside the
host; it rapidly loses infectivity after contact with organic solvents and pH outside the range of 6.7–9.3,
with sensitivity to low pH increasing with environmental temperatures from 4 to 37°C (Stevens, 2009).
The same author also examined the ability of BVDV to survive over a 96-h period on/in a range of
surfaces and liquids, with or without mucus, including paper, latex gloves, cotton T-shirt, denim jeans,
untreated pine wood, rubber boot, galvanised and enamelled buckets, mineral and salt blocks, total
mixed ration (TMR), pen ﬂoor soil/manure, water and phosphate buffered saline (PBS).
The probability of virus being present decreased with time, with survival enhanced by the presence
of mucus. Modelling predicted no virus present at 96 h in all cases. Virus survival was most prolonged
in water and PBS, followed by on latex and enamelled metal, paper, galvanised metal, soil and pine
and TMR. No virus was recovered from the cotton T shirt, denim, mineral or salt licks (Stevens, 2009).
Slurry: 105.2 TCID50/50 lL of BVDV was fully inactivated after 3 weeks, 3 days, 3 h, 50 min,
20 min, 5 min and 5 mins at temperatures of 5, 20, 35, 40, 45, 50 and 55°C, respectively (Bøtner and
Belsham, 2012).
Whole milk: BVDV was inactivated when whole milk was heated at 85–92.2°C for 10 min
(although viral RNA could still be detected in some samples) (Marley et al., 2009).
Whole and ground meat: BVDV was consistently inactivated when cooked to ≥ 75°C (Bratcher
et al., 2012).
BVDV is resistant to dry heat, not being signiﬁcantly inactivated by one hour’s exposure to
temperatures between 75 and 95°C (Sauerbrei and Wutzler, 2009).
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Horizontal: Direct (nose to nose) and airborne over short distances in buildings where persistently
infected animals are present and indirect via contaminated equipment, facilities and personnel (Gunn,
1993). Spread of BVDV by ambient air or other vehicles involving TI animals has never been
demonstrated and is most to be of marginal signiﬁcance (Lindberg and Houe, 2005). Virus may be
shed in the semen of bulls (Rikula et al., 2008), but avoidance of transmission by this route during
artiﬁcial insemination using semen collected in MSs can be achieved through compliance with the
requirements for intracommunity trade laid down in Council Directive 2003/43/EC1 or the OIE
guidelines on collection and processing of bovine, small ruminant and porcine semen (OIE, 2016b).
BVDV can also be transmitted by embryo transfer, but preliminary evidence indicates that the risk is
negligible if in vivo embryos are collected and processed according to OIE guidelines (OIE, 2016a).
Adventitious transmission by contaminated live vaccines has also been described (Løken, 1995). Virus
has been recovered from biting and non-biting ﬂies following exposure to PI animals in experimental
studies, but with one exception onward transmission of the virus has not been demonstrated (Gunn,
1993; Rikula et al., 2008; OIE, 2016b).
Vertical: Transient infection of a na€ıve dam during the ﬁrst third of pregnancy (up to
approximately 125 days of gestation) will result in the birth of a PI calf if the foetus is carried to term.
All calves born to PI dams will also be PI.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not relevant.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
See below.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
A basic reproduction ratio (R0) of 0.25 (95% CI 0.01; 1.95) and 0.24 (95% CI 0.01; 2.11) was
estimated for TI animals infected with a virulent BVDV-1b and a virulent BVDV-2a ﬁeld isolate from
Belgium, respectively. After introduction of a PI animal, an R0 of +∞ (95% CI 1.88; +∞) was
calculated. These results support the suggestion that TI animals, compared to PI animals, contribute
only a limited amount to BVDV spread (Sarrazin et al., 2014).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU (Figure 1)
1 Council Directive 2003/43/EC of 26 May 2003 amending Directive 88/407/EEC laying down the animal health requirements
applicable to intra-Community trade in and imports of semen of domestic animals of the bovine species. OJ L 143, 11.6.2003,
p. 23–32.
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Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
The disease is considered endemic in all MS in the absence of systematic eradication programmes
(Tables 1 and 2).
Where a systematic approach has been adopted in MS, signiﬁcant progress has been made. The
Scandinavian countries Sweden, Finland and Denmark have completed eradication programmes
(as has Norway) (Stahl and Alenius, 2012; Løken and Nyberg, 2013; Foddai et al., 2014; Norstr€om
et al., 2014; Finnish Food Safety Authority Evira, 2016), while national or regional programmes are
under way and have reduced the prevalence of PI births in a number of other MSs, including Austria,
Germany, Ireland, Austria, Scotland and Belgium (Rossmanith et al., 2010; Schirrmeier et al., 2012;
Clegg et al., 2016; Duncan et al., 2016; Ribbens et al., 2016) and in Switzerland (Presi et al., 2011).
Risk of introduction
Infection is already present in MS.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
A range of reliable diagnostic tools for detection of virus, viral antigens, RNA and antibodies are
available (see Section 3.1.4.1. Parameter 1).
Control tools
Parameter 2 – Existence of control tools
Three central elements of systematic approaches to control and eradication of BVDV have been
identiﬁed (Lindberg et al., 2006):
Figure 1: Distribution of BVD in Europe in domestic and wild animals species from January to June
2016 (Source: OIE-WAHIS)
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a) biosecurity and possible use of vaccination (Lindberg et al., 2006) aimed at preventing
re-introduction of the infection in free herds
b) elimination of PI animals from infected herds
c) surveillance to monitor the progress of interventions and to rapidly detect new infections.
These have been applied independently, in a number of European countries, with Scandinavia now
considered free of infection. Compulsory independent national or regional programmes are currently
underway in a number of other countries, including Austria, Belgium, Ireland, Northern Ireland,
Germany, Scotland and Switzerland (Stahl and Alenius, 2012; Sarrazin et al., 2013). These
programmes are not compulsory on an EU level.
However, EU level measures are in place to prevent trading of bovine semen and embryos from
BVDV-infected donor animals. Council Directive 2003/43/EC lays down the animal health requirements
applicable to intra-Community trade and imports of semen of domestic animals of the bovine species.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
As noted above in Section 3.1.1.7 Parameter 1, a number of MSs have independent eradication
programmes underway. However, currently, only Denmark, Sweden and Finland have completed
eradication and therefore the disease is considered still present in all other MSs.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Health and production losses from observational studies are summarised in Table 3. Losses
attributable to BVD arise from three main sources- reproductive losses, immunosuppression in calves
and persistently infected animals (Gunn et al., 2004). Estimates of economic/ﬁnancial losses due to
BVDV associated with initial outbreaks, the average losses at herd level and at national livestock level
have been reviewed in the Report on the EU Thematic Network on control of BVDV. Various studies were
carried out on the average ﬁnancial losses for cattle herds. The estimations range from €30 to €60 per
average cow present. At the level of the national livestock sector, studies indicated a loss due to BVDV
under endemic conditions of € 15–20 per cow present. Compared to other production diseases such as
mastitis and lameness, the ﬁnancial-economic importance of BVDV can be considered as ‘moderate’.
Some results are summarised in Tables 5, 6 and 7 for some countries (EU Thematic network on
control of bovine viral diarrhoea virus (BVDV), 2001).
Table 5: Summary of ﬁnancial-economic losses due to initial outbreaks of BVDV (data extracted
from the EU Thematic network on control of bovine viral diarrhoea virus (BVDV) (2001))
Country Herd type Loss per cow/year (range) Year
UK Dairy £137 1999
UK Dairy £39–92 1986
Netherlands Dairy €45 1998
Netherlands Dairy €19–130 1990
Denmark Dairy €30–89 1994
Canada Dairy €240–600 1998
Table 6: Summary of average ﬁnancial-economic losses at herd level due to BVDV (data extracted
from the EU Thematic network on control of bovine viral diarrhoea virus (BVDV) (2001))
Country Herd type Cost per cow/year (range) Year
Canada Dairy €34 2002
UK Dairy £31 2000
UK Beef £32–43 2004
France Dairy €60–100 2004
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The variation in the economic impact of BVDV at dairy farm level in a number of MS arising from
uncontrolled output following introduction to a BVDV-naıve herd within year 1 of a 10-year epidemic
represented 22%, 7%, 8%, 5%, 8% and 20% of the BVDV-free annuity for the UK, Northern Portugal,
Holland, Norway, Italy and Germany, respectively (Gunn et al., 2005).
Total loss attributable to infection with BVDV in New Zealand dairy herds was estimated at NZ$87
per cow/year in affected herds, and NZ$44.5 million per year overall, based on an estimated 14.6%
affected herds (Heuer et al., 2007).
The maximum annual output losses per cow in 50-cow suckler (cow-calf) beef herds in Scotland
where the herd was either initially BVDV-free or of unknown status were estimated at £38.71 and
£28.22, respectively (Stott et al., 2012).
The average annuity equivalent of unchecked losses due to BVDV infection and re-infection in
typical British hill suckler (cow-calf) enterprises over a 10-year disease ranged from almost £0/cow to
approximately £40/cow per year, depending on the initial disease status of the herd, the initial source
of virus, the probability and source of further infection, the probability of virus transmission within the
herd and herd size (Gunn et al., 2004).
Based on data for 1993, the annual ﬁnancial loss due to BVD in Norway in the absence of control
was estimated at approximately NOK 32.5 million (Valle et al., 2005).
The annual losses to the Irish cattle industry due to BVDV were estimated at €102 million (Stott
et al., 2012) (cattle population estimate in 2016: 6,613,400; Central Statistic Ofﬁce Ireland).
Using an economic welfare model, the net discounted economic gain for Scotland of eradicating
BVD from the Scottish dairy herd was estimated at £47 million over a 10-year eradication period
(Weldegebriel et al., 2009).
The annual cost of BVDV in the Australian cattle population was estimated to be AUS $57.9 million
(Lanyon and Reichel, 2014).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Clinical signs may vary from inapparent to death, depending on a variety of factors including
whether the animal is acutely or persistently infected.
Acute (transient) infections: Transient infection of na€ıve female breeding animals may have a
range of negative outcomes depending on the stage of reproduction, including fertilisation failure,
early embryonic death, abortion, congenital defects and the birth of PI offspring which may be weak,
undersized and ill-thrifty; infection of na€ıve bulls may result in decreased sperm motility and density
and increase levels of sperm abnormalities (Lanyon et al., 2014). Other clinical signs associated with
acute infection include pyrexia, diarrhoea, decreased milk yield, sudden death and haemorrhagic
syndrome (Ridpath et al., 2013; Lanyon et al., 2014; Gethmann et al., 2015).
However, the majority of acute infections are considered subclinical, with seroconversion and
recovery occurring 2–3 weeks post-infection (Ridpath et al., 2013; Lanyon et al., 2014). Even in the
absence of clinical signs infection of a BVDV, na€ıve animal results in a transient viraemia which can be
associated with short-term leukopenia, lymphopenia and/or thrombocytopenia, apoptosis in the
thymus, and pyrexia. The resultant immunosuppression, particularly in calves, can allow other
infectious agents to become established, or allow the recrudescence of existing infections resulting in
enteric or respiratory disease which may be fatal. Recent work demonstrating a signiﬁcant reduction in
thymic size following challenge of calves with both low and high virulence BVDV strains, accompanied
Table 7: Summary of ﬁnancial-economic losses at the national livestock sector level (data extracted
from the EU Thematic network on control of bovine viral diarrhoea virus (BVDV) (2001))
Country Loss at national level Year
UK £5–30 million 1999
UK £40 million 2003
Denmark €20 million/1M calving 1993
Denmark €52 million/1M calving (high virulence strain) 1993
AHL assessment on bovine viral diarrhoea (BVD)
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2017;15(8):4952
by a signiﬁcant depletion of thymic cortex, suggests that transient infection of neonatal calves may
have long-term immunosuppressive effects (Ridpath et al., 2013). Following the emergence of BVDV II
in North America, much higher case morbidity rates (and mortality rates) associated with primary
infection were reported (Carman et al., 1998). The within-herd abortion rate was 44% (3–83%). The
mortality rate was 53% (3–83%) for animals under 2 years of age and 9% (2–26%) for older animals.
A recent study of BVDV type 2c in Germany reported a case-fatality rate of up to 60% while mortality
in outbreak farms varied between 2.3% and 29.5% (Gethmann et al., 2015).
Persistent infections: PI animals can be clinically healthy, but some may appear small, weak and
ill-thrifty, showing decreased weight gain, stunted growth and chronic ill thrift. PI animals are
considered more susceptible to secondary infections (Lanyon et al., 2014) leading to poor survivability
of most PI animals. The annual incidence risk of dying or being slaughtered due to unthriftiness was
calculated as 0.28 and 0.31 among 34 PI animals in 10 Danish dairy herds (Houe, 1993).
In addition, PI animals are uniquely to susceptible to developing mucosal disease, which is inevitably
fatal (Lanyon et al., 2014), with death occurring a few days to a few weeks following its onset.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
The CITES list contains a number of species in the Families Antilocapridae, Bovidae, Cervidae,
Camelidae and Suidae, within the Order Artiodactyla. However, there is no speciﬁc data conﬁrming
their susceptibility to infection with BVDV (although a related pestivirus has been isolated from
pronghorn (Ridpath and Neill, 2016).
Parameter 2 – Mortality in wild species
Despite abundant evidence that pestiviruses currently circulate in wildlife populations, the full
impact of exposure and prevalence of these infections are largely unknown (Ridpath and Neill, 2016).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
BVDV does not survive for extended periods in the environment (see Section 3.1.1.5 Parameter 4).
Despite abundant evidence that pestiviruses currently circulate in wildlife populations, the full impact of
exposure and prevalence of these infections are largely unknown (Ridpath and Neill, 2016).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
CFSPH (http://www.cfsph.iastate.edu/DiseaseInfo/): No
OIE (http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2016/): Yes
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
(http://www.australiagroup.net/en/human_animal_pathogens.html): No
Parameter 3 – Included in any other list of potential bio-agroterrorism agents
None identiﬁed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
A range of direct and indirect test methods for BVDV are described in OIE (2015), with these being
further categorised according to the purpose of the test (Table 8). Within Europe, availability of
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laboratories offering tests for both agent identiﬁcation and detection of the immune response is high,
with these commonly accredited to ISO 17025. Kits are readily available commercially.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
See Table 9. It is important that all assays are appropriately validated before use, particularly in
relation to their ability or otherwise to detect both BVDV 1 and 2 (and other related pestiviruses)
(Bauermann et al., 2012).
Table 8: Test methods available for diagnosis of bovine viral diarrhoea and their purpose
(reproduced from OIE (2015))
Method
Purpose
Population
freedom
from
infection
Individual
animal
freedom
from
infection
prior to
movement
Contribution
to eradication
policies
Conﬁrmation
of clinical
cases
Prevalence
of infection-
surveillance
Immune
status in
individual
animals or
populations
post-
vaccination
Agent identiﬁcation
Virus
isolation
+ +++ ++ +++ – –
Antigen
detection
by ELISA
++ +++ +++ +++ +++ –
IHC – – – ++ – –
NA
detection
by real time
RT-PCR
+++ +++ +++ +++ +++ –
Detection of immune response
ELISA +++ ++ +++ – +++ +++
VN + +++ ++ – + +++
Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or other
factors severely limits its application; – = not appropriate for this purpose. Although not all of the tests listed as category +++ or
++ have undergone formal validation, their routine nature and the fact that they have been used widely without dubious results,
makes them acceptable.
IHC: immunohistochemistry; NA: nucleic acid; VN: virus neutralisation.
Table 9: Performance characteristics for diagnostic tests and comments thereon
Method
Commonly tested
matrices
Se Sp Comments
Agent identiﬁcation
Virus
isolation
Serum, buffy coat,
leucocytes, whole
blood, tissues, semen
100% 100% • Historically considered the gold standard
Lanyon et al. (2014) but less commonly
used now due to issues of time, cost and
requirement for cell culture
• Toxicity to cell cultures can be an issue,
especially with semen
• Maternally derived antibodies (MDA) may
interfere with isolation from serum in
young calves
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Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
See Table 9.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Both live and dead (inactivated vaccines are available (see below).
Parameter 2 – Availability/production capacity (per year)
A search of the websites of the European Medicines Agency (http://www.ema.europa.eu/ema) and
the Health Products Regulatory Authority (http://www.hpra.ie/homepage/veterinary) on 15.10.16
provided details of three vaccines currently licensed for use in one or more MSs with datasheet claims
relating to fetal protection (Table 10). No DIVA vaccines are currently licensed. All vaccines licensed in
MSs with a claim relating to fetal protection must satisfy the requirements of the BVD Monograph of
the European Pharmacopoeia.
Method
Commonly tested
matrices
Se Sp Comments
Antigen
detection
by ELISA
Serum, plasma, whole
blood, tissues
(including ear notch)
93.5–100%
Hilbe et al.
(2007) and
Presi and
Heim (2010)
99–100%
Hilbe et al.
(2007) and
Presi and
Heim (2010)
• Not intended for the detection of acutely
infected animals, although may
occasionally do so
• The Erns ELISA may be less effective in
young calves in the presence of MDA
when testing serum Fux and Wolf (2013)
• The NS2-3 ELISA may be less effective in
young calves in the presence of MDA
when testing serum or tissue Fux and
Wolf (2013)
Antigen
detection
by IHC
Tissue 100%
Cornish et al.
(2016)
Not available • Skin biopsies such as ear notch samples
have been shown to be useful for in vivo
detection of PI animals Cornish et al.
(2016)
• While perceived as robust and suitable
for large numbers of tissue samples, it is
labour intensive, prone to technical error,
relies on a subjective scoring system,
requires experienced personnel to ensure
accuracy and is unreliable for use on
samples stored in formalin for > 15 days
Lanyon et al. (2014)
NA
detection
by real
time
RT-PCR
Serum, buffy coat,
leucocytes, whole
blood, tissues, semen,
milk, bulk tank milk
97.1–100%
Hilbe et al.
(2007) and
Presi and
Heim (2010)
99–100%
Hilbe et al.
(2007) and
Presi and
Heim (2010)
• High analytical sensitivity allows pooled
samples (ear notch, serum) and bulk
tank milk to be tested
• Detection of viral RNA does not imply per
se that infective virus is present
Detection of immune response
ELISA Serum, milk, bulk tank
milk
Up to 98%
Presi and
Heim (2010)
Up to 99%
Presi and
Heim (2010)
• Both indirect and blocking assays are
commercially available
• Indirect more sensitive for bulk tank
testing Foddai et al. (2015)
VN Serum 100% 100% • Considered the gold standard test, but
time-consuming and expensive to
perform
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BVD vaccines are widely available in Europe and worldwide, but speciﬁc data on production
capacities are lacking.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
All vaccines licensed in MSs with a claim relating to foetal protection must satisfy the requirements
of the BVD Monograph of the European Pharmacopoeia.
The role of vaccines in systematic control is as an additional biosecurity measure. In areas where
the risk of introducing BVDV infection is known or perceived to be high, one option is to implement
systematic vaccination in the initial stages of control/eradication programmes, after removal of PI
animals. The need for including a vaccination regime will differ between countries/regions and it will
also change over time, as the prevalence of infected herds decreases (EU Thematic network on control
of bovine viral diarrhoea virus (BVDV), 2001). Even in this context, there are a number of additional
factors that require consideration before using vaccines, including antigenic variation between vaccine
and ﬁeld strains, incorrect use of vaccines, lack of common understanding of the purpose of
vaccination, the desirability of 100% efﬁcacy of foetal protection, importance of complying with wider
programme elements (not just vaccination), diagnostic confounding and the potential for live BVDV
vaccines to be contaminated with adventitious viruses (Lindberg et al., 2006). There is little
information available on the ﬁeld efﬁcacy of vaccines. A meta-analysis of the efﬁcacy of BVDV
vaccination to prevent reproductive disease measured by risk of foetal infection, abortion risk and
pregnancy risk revealed signiﬁcant decreases of nearly 45% in abortions and nearly 85% in foetal
infection rate in vaccinated cattle compared with unvaccinated cohorts (Newcomer et al., 2015). When
data relating to ﬁeld challenge only were included, abortion risk was signiﬁcantly reduced by 33%,
while insufﬁcient data were available for analysis regarding the risk of foetal infection. Additionally,
pregnancy risk was increased by approximately 5% in ﬁeld trials of BVDV vaccinates. It should be
noted although that many of the vaccines used in this study are not licensed for use in the EU.
Parameter 4 – Duration of protection
See Table 10.
Feasibility
Parameter 5 – Way of administration
See Table 10.
Table 10: Selected details of licensed BVD vaccines taken from their Summary of Product
Characteristics
Name of the
Veterinary
Medicinal Product
Type (live/dead)
and strain(s)
Way of
administration
Duration of
immunity/booster
interval
Manufacturer
Bovela lyophilisate
and solvent for
suspension for
injection for cattle
Modiﬁed live bovine viral
diarrhoea virus type 1,
non-cytopathic parent
strain KE-9 and modiﬁed
live bovine viral diarrhoea
virus type 2, non-
cytopathic parent strain
NY-93
Intramuscular
injection
1 year Boehringer
Ingelheim
Bovidec Bovine viral diarrhoea
(BVD) virus strain
KY1203nc (inactivated)
Subcutaneous
infection
A single annual
booster dose is
recommended
Novartis Animal
Vaccines Ltd
Bovilis BVD
Suspension for
injection for cattle
Inactivated antigen of
cytopathogenic BVDV
strain C-86
Intramuscular
injection
One vaccination every
6 months
MSD Animal
Health
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3.1.4.3. Article 7(d)(iii) Medical treatments
No antiviral drugs are available for treating infection with BVDV.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Biosecurity measures seek to either:
• Prevent introduction of PI animals and carriers OR
• Prevent dams in early pregnancy from having direct or indirect contact with sources of BVD
virus to avoid creation of PI calves. Lindberg and Alenius (1999) have reviewed risk factors for
the introduction of BVDV into non-infected herds, evaluated the perceived need for control for
each of these and proposed relevant control measures (Table 11).
Table 11: Risk factors for the introduction of BVDV and their need for control (Lindberg and
Alenius, 1999)
Risk
Perceived
need for
control
Plausible ways through
which BVDV is
introduced into a
non-infected herd
Comments Proposed control
Livestock
trade
Imperative Purchase of:
1) A PI animal
2) A dam carrying a PI
calf
3) A seronegative animal
in early pregnancy,
infected during trade
4) Other animals which
has attained transient
infection during trade
and transmit virus to
newly pregnant
non-immune animals
in the destination
herd
a) Effect on disease
spread by PIs in the
market will be
multiplied if contacts
with seronegative
animals in early
pregnancy can occur
b) Prevalence of dams
carrying PIs likely to
be higher than
prevalence of PI
animals. The latter
has been estimated
to 1  2% in an
endemic situation
Houe (1995)
c) Transiently infected
animals are regarded
as low impact
transmitters Niskanen
et al. (1996)
Test for virus and
antibodies in herd of
origin
Stop viraemic animals
and pregnant animals
with high titres from
being traded (control
of 1, 2)
Recommend
quarantine with
re-test after 4 weeks
(control of 3, 4)
Create a framework
for trade between
non-infected herds,
based on herd
samples to prove
freedom from disease
(certiﬁcation system)
Exhibitions Yes 1) Seronegative animals
in early pregnancy
becomes infected at
the exhibition
2) An animal which has
attained a transient
infection and
succeeds in infecting
newly pregnant
non-immune animals
after returning home
a) PIs present at
exhibitions will
constitute a severe
risk for farmers
bringing seronegative
animals in early
pregnancy
b) Transiently infected
animals are regarded
as low impact
transmitters
Test for virus and
antibodies in herd of
origin, before
exhibition
After exhibition: Four
weeks quarantine and
retest if seronegative
prior to exhibition. or
Arrange exhibitions for
animals from certiﬁed
BVD-free herds only
Freedom from disease
should be reinsured
by recently performed
herd level retests
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Risk
Perceived
need for
control
Plausible ways through
which BVDV is
introduced into a
non-infected herd
Comments Proposed control
Animal
contacts on
pasture or
over fences
Yes 1) Seronegative animals
in early pregnancy
become infected on
pasture
2) Some other animal
attains transient
infection and
subsequently
transmits the infection
to other, newly-
pregnant non-immune
animals in the herd
a) Not controlling for
the release of PIs on
common pastures will
constitute a severe
risk for farmers
pasturing
seronegative animals
in early pregnancy
b) PI carrying dams
may spread disease if
they abort or calve
on pasture
c) From a disease point
of view, and in terms
of herd incidence,
over-fence contacts
will be less important
than common
pasturing
Intentional contacts:
Same principle as for
exhibitions
Unintentional
contacts: Follow-up
testing for antibodies
(paired serum
samples)
As an alternative, the
animals with which
contact has occurred
could be tested for
antibodies and virus
Live vaccines In the
context of
BVDV
control, the
use of live
BVDV
vaccines
should be
banned until
safe
At least one susceptible
animal in early pregnancy
becomes infected due to
usage of live vaccine
contaminated with non-
cytopathic BVDV strains in
the production process, or
disease emerge as a result
of recombinations between
vaccines and ﬁeld strains
Ridpath and Bolin (1995)
and Desport et al. (1996)
Risk of introducing strains
new to the cattle population
in question
No vaccination or use
of inactivated vaccines
only
Semen and
embryos
Yes At least one susceptible
animal in early pregnancy
becomes infected by other
dams transiently infected
due to AI with semen from
PI bull or transiently infected
bull, or persistent foetal
infection develops in dam
receiving AI with semen
from PI bull or transiently
infected bull
Risk of introducing strains
new to the cattle population
in question
A case has been reported
with a seropositive bull
constantly shedding virus in
semen in the absence of
general persistent infection
Voges et al. (1998)
Although this phenomenon
is probably of low frequency
occurrence, it should be
noted that such bulls could
only be detected by testing
semen
Test for antibody and
virus on all bulls
entering AI stations
Regular testing for
antibodies on
seronegative bulls
during study period.
(Test of semen from
antibody positive
bulls)
Embryo donors should
come from herds free
from BVDV and
embryos should be
protected from BVDV
contamination during
the transfer process
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Risk
Perceived
need for
control
Plausible ways through
which BVDV is
introduced into a
non-infected herd
Comments Proposed control
Visitors,
including
vets, AI
technicians
and herdsmen
in the
replacement
system
Unlikely to
be of major
importance
and impact,
but
preventative
measures
are
appropriate
in scheme
rules
At least one susceptible
animal in early pregnancy
becomes infected due to
contact with inadequately
cleaned and/or disinfected
boots, instruments and
similar
Risk for transmission will
depend upon:
• Time interval
between visit in
infected/non-
infected herd
(Prevalence of
infection in the
area)
• Type of vehicle
(faeces, clothes,
instruments Gunn
(1993),
contaminated
injectables) and
amount of virus
transmitted Houe
(1999)
• Pregnancy and
immune status of
in-contact animal(s)
in the herd
Normal hygienic
measures should be
taken by professionals
with ambulatory
services to farmers as
well as other visitors
For veterinarians: use
knowledge about
BVDV status of herds
to plan routes or to
call for change of
clothes
On-farm
collection of
slaughter
animals or
brokered
calves by
professional
transportation
staff
Preventative
measures
are
appropriate
in scheme
regulations
At least one susceptible
animal in early pregnancy
becomes infected due to
contact with a persistently
infected sheep/pig/goat/pig/
deer/elk
No evidence exists that wild
ungulates, swine or goats
have transmitted the
infection to cattle, even
though interspecies
transmission is possible
Nettleton (1990). Strains
proven to be involved in
transmission from sheep to
cattle have been of bovine
origin Paton et al. (1995).
BVD control was not
compromised by sheep
when implemented on the
Shetland Islands Synge
et al. (1999)
Check prevalence of
Border disease in the
area and judge
whether problem
exists
If so, require sheep
from herds with a
previous history of
Border disease and
sheep in close contact
with BVDV-infected
cattle herds to be
tested free from
BVD/BVDV before
introduction into
non-infected herds.
Exception can be
made for sheep
certiﬁed BVDV-free
farms
Vectors (ticks,
mosquitoes,
ﬂies)
No, at least
not in the
temperate
climate
zones
At least one susceptible
animal in early pregnancy
becomes infected due to
contact with virus-carrying
vector
Insects, such as biting ﬂies
have been shown to be
capable of carrying BVDV
under experimental
conditions Tarry et al.
(1991). Vector-borne
transmission has never been
described under natural
conditions
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Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Overall, the effectiveness of available biosecurity measures in preventing the entry of BVDV by
direct or indirect routes is considered high when applied appropriately. One exception relates to the
introduction of pregnant non-PI females carrying PI calves (referred to as Trojan animals) (Lanyon
et al., 2014).
Feasibility
Parameter 3 – Feasibility of biosecurity measure
The biosecurity measures described are considered feasible. This has been proven by the number
of successfully applied eradication programmes.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
The key restriction measure relates to the movement of PI animals. This is readily available through
prior testing. Identiﬁcation of Trojan dams by diagnostic testing prior to movement is not available, but
has been addressed in eradication programmes by applying restrictions at herd level for a period
following removal of PI animals (EU Thematic network on control of bovine viral diarrhoea virus
(BVDV), 2001). Movement of TI animals is considered a much lower risk but is more difﬁcult to
address. A range of reliable diagnostic tools for detection of virus, viral antigens, RNA and antibodies
are available (see Section 3.1.4.1. Parameter 1).
Additionally, measures are in place to prevent trading of bovine semen and embryos from
BVDV-infected donor animals. Council Directive 2003/43/EC lays down the animal health requirements
applicable to intra-Community trade and imports of semen of domestic animals of the bovine species.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
Prevention of movement of PI animals is considered key to control. The effectiveness of movement
controls is clearly dependent on the level of uptake/industry engagement, being most effective in the
context of systematic control and least effective when participation/involvement is voluntary (Lindberg
et al., 2006).
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
PI animals comprise a small percentage of the population (Houe, 1999) and therefore restricting
their movement is feasible. Restricting movements of pregnant females from herds where BVDV has
been identiﬁed until sufﬁcient time has elapsed to minimise the possibility of the sale of pregnant
animals carrying PI calves is also feasible, but is more disruptive to trade and will affect a larger
proportion of animals. Measures to prevent movement of TI animals are likely to have a greater
impact still, although the duration of the measure at herd level is likely to be much shorter.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
PI animals are not excluded from the food chain subject to passing appropriate ante- and
post-mortem inspection. Therefore, slaughter is normally carried out in abattoirs. Where juvenile PI
animals are being culled, there are typically one or a small number of animals per herd which can be
slaughtered by veterinary practitioners or knackery operators.
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Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Identiﬁcation and removal of PI animals is recognised to be key to stopping the spread of infection,
both within and between farms.
Feasibility
Parameter 3 – Feasibility of killing animals
Disposal of small numbers of PI animals either through abattoirs or on farm is feasible (and already
happening in eradication programmes).
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Depending on the age and health of the animal, carcasses and by-products may be disposed of
through the abattoir system or by rendering.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Currently available disposal options are considered effective.
Feasibility
Parameter 3 – Feasibility of disposal option
Disposal via abattoir or rendering is already routine.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
Epidemiological-economic models used to develop a number of decision support tools in several
countries at both herd and sectoral/national levels have been reviewed previously (EU Thematic
network on control of bovine viral diarrhoea virus (BVDV), 2001). Overall the results at both levels
were contradictory, with all studies having in common an emphasis on reducing the risk of
re-introduction of BVDV as this had negative consequences on the ﬁnancial-economic feasibility of
prevention and control.
A recent systematic review of economic evaluations of worldwide BVDV control activities found that
most studies provided only qualitative values of control activities and did not include an economic
methodology in their study design (Richter et al., 2016).
A loss-expenditure frontier method was used to compare control strategies in Scottish suckler
(cow-calf) beef herds to identify strategies with the maximum net beneﬁt from combining output
losses and control expenditure (Stott and Gunn, 2008). Consistent with a previous report (Houe,
2003), there was no single strategy that generated the best outcome; while the mean net beneﬁt was
consistently positive, it varied with herd size and initial herd status (na€ıve or unknown).
A study of producer and consumer beneﬁts arising from eradication of BVDV from Scottish dairy
herds estimated that while there was an overall discounted economic gain of £47 million over
10 years, this was unevenly distributed, with milk consumers gaining £11 million and producers with
infected herds gaining £39 million, while those with uninfected herds lost £2 million (Stott et al., 2010).
Parameter 2 – Cost of eradication (culling, compensation)
In contrast to other diseases, eradication of BVDV, be it from individual farms or complete livestock
sectors, is possible. In other words, the potential gross beneﬁts of eradication of BVDV might be larger
than those of other diseases. The costs of such programmes can apparently vary quite a lot, thereby
affecting their beneﬁt/cost ratio (BCR). The Norwegian study shows positive ﬁnancial-economic effects
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(i.e. a BCR larger than 1) already over a 10-year period, when the annual BVD programme costs were
subtracted from the beneﬁts, a net positive value for the entire period of NOK 130 million (Valle et al.,
2005). In contrast, in a French study where it took approximately 15 years to reach breakeven.
It should be noted that these two examples applies clearly different control schemes. However, no
single advice applicable for all situations exist. Speciﬁc conditions could determine the proﬁtability of
nation-wide programs (EU Thematic network on control of bovine viral diarrhoea virus (BVDV), 2001).
Analyses of Scandinavian programmes have shown a positive cost beneﬁt. For example Houe
(Houe, 2003) reports costs associated with the ﬁrst 3 years of the Danish eradication programme of
approximately $9 million/year, with annual costs of approximately $3.5 million for the following
4 years, with this total of some $41 million cost over 7 years set against annual losses estimated at
$20 million prior to eradication.
More recent studies have also proposed a positive cost-beneﬁt to control of BVDV in dairy herds. In
New Zealand, the annual cost of BVDV infection to the dairy industry was estimated to be in excess of
NZ $23 million per annum, while a range of control options gave rates of return over a 10-year term
as high as 123% (Reichel et al., 2008).
In the Netherlands, the average annual net costs associated with bovine viral diarrhoea were
estimated at €27.8 million for the dairy industry, with the most favourable control option examined
yielding a positive cost-beneﬁt of 1.5 over a 10-year period (Santman-Berends et al., 2015).
A study in Ireland predicted the costs of a national eradication programme in Ireland to be €55
million over a 6-year period, generating a positive cost beneﬁt against the estimated annual losses due
to BVDV of €102 million (Stott et al., 2012).
Parameter 3 – Cost of surveillance and monitoring
Surveillance and monitoring costs have not been reported by MSs that have completed eradication
but are typically based on targeted serological screening of herds using samples including bulk tank
milk samples and blood samples collected at abattoirs (Foddai et al., 2014; Norstr€om et al., 2014).
Surveillance and monitoring costs should therefore be lower than eradication costs.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Figures are not available.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector
Figures are not available.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The control and eradication programmes that have either been completed or are currently underway
in a number of Member States (Stahl and Alenius, 2012) have had good societal acceptance.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Control measures which result in the identiﬁcation and removal of PI animals are anticipated to
have a strongly beneﬁcial impact on the welfare of domestic animals by preventing transient infections
in this population. The vaccines currently used in the EU are not expected to have side effects such as
fetopathy, induction of mucosal disease and immunosuppression impacting on welfare that have been
attributed to MLVs used elsewhere (Kelling, 2004; Ridpath, 2013; Griebel, 2015).
Parameter 2 – Wildlife depopulation as control measure
Depopulation of wildlife has not been implemented as a control measure for BVDV.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Biocides and medicinal drugs are not used for control of BVDV.
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Biodiversity
Parameter 2 – Mortality in wild species
Control measures are not anticipated to result in mortality in wild species.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about BVD (Table 12). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 13. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Outcome of the assessment of bovine viral diarrhoea according to criteria
of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 12, BVD
complies with all criteria of the ﬁrst set and with two criteria of the second set, therefore it is
considered eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about bovine viral diarrhoea (Tables 13, 14, 15, 16 and 17). The
Table 12: Outcome of the expert judgement on the Article 5 criteria for bovine viral diarrhoea
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No); red = not applicable (na), i.e. insufﬁcient evidence or not relevant to judge.
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expert judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria
(see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement
on each criterion of Article 9, and the reasoning supporting their judgement. The minimum number of
judges in the judgement was 13. The expert judgement was conducted as described in the
methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions,
see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 13: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV (category
A of Article 9) for bovine viral diarrhoea (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory
of the Union
N
2.1 The disease is highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
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Table 14: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for bovine viral diarrhoea (CI = current impact; PI = potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
Y
2.1 The disease is moderately to highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 15: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for bovine viral diarrhoea (CI = current impact; PI = potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
NC
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 18, 19,
20 and 21). The proportion of Y, N or `na0 answers are reported, followed by the list of different
supporting views for each answer.
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 16: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for bovine viral diarrhoea
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 17: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for bovine viral diarrhoea
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
Y
Colour code: green = consensus (Yes/No).
AHL assessment on bovine viral diarrhoea (BVD)
www.efsa.europa.eu/efsajournal 35 EFSA Journal 2017;15(8):4952
Reasoning supporting the judgement
Supporting Yes for 2.1 (cat.A):
• PI animals infect a large proportion of susceptible bovines which they come in contact with,
thus in herds with PI being present, a very high percentage of the herd will be infected.
Supporting Yes for 2.1 (cat.B,C):
• Transmission rate varies depending on the type of infected animal (for PI animals is high for TI
is lower) and on the contact structure on the farm.
Reasoning supporting the judgement
Supporting Yes for 2.4 (cat.A):
• The disease may result in high morbidity as high numbers of animals may be infected when PI
animals are present. Mortality can be signiﬁcant due to high case-fatality in PI animals.
Supporting Yes for 2.4 (cat.B):
• Most animals are infected with acute infection and then cured. Only PI animals eventually die.
• High number of animals may be TI by a PI.
Supporting Yes for 2.4 (cat.C):
• In endemic situations, there may be some mortality in PI animals, but production losses are
the most observed effect.
Table 18: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question Final outcome
Response
Y (%) N (%) na (%)
2.1(cat.A) The disease is highly transmissible NC 77 23 0
2.1(cat.B,C) The disease is moderately to highly transmissible NC 23 77 0
NC: non-consensus; number of judges: 13.
Table 19: Outcome of the expert judgement related to criterion 2.4 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.4(cat.A) The disease may result in high morbidity and
signiﬁcant mortality rates
NC 8 0 0
2.4(cat.B) The disease may result in high morbidity with
in general low mortality
NC 23
2.4(cat.C) The disease usually does not result in high
morbidity and has negligible or no mortality AND often
the most observed effect of the disease is production loss
NC 69
NC: non-consensus; number of judges: 13.
Table 20: Outcome of the expert judgement related to criterion 5(b)(CI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 84 8 8
NC: non-consensus; number of judges: 13.
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Reasoning supporting the judgement
Supporting Yes:
• Currently, the disease is limited to MSs without voluntary control programmes (and those at
the start of a programme). Primarily, it is a welfare concern (particularly in calves) in sequelae
associated with transient infection. There is evidence for an abortion rate of 44%.
• Secondary infections can have an impact on animal welfare.
Supporting No:
• Most animals are subclinically infected, thus there is no welfare concern. If there really was,
trade without any controls would not be freely allowed and eradication would be compulsory
rather than voluntary.
Supporting na:
• There is only data about the American situation and no evidence indicating that large numbers
of animals could be affected in Europe.
Reasoning supporting the judgement
Supporting Yes:
• BVD would impact all MSs if current controls were relaxed. There would be welfare implications
for all animals that present with clinical signs.
• If BVDV is introduced to a na€ıve population, there are abortions, stillbirths and weak calves
with persistent infection. This affects welfare in the affected farms.
Supporting No:
• Currently, there are no EU wide controls on BVD. Some MSs are BVD-free and recognised as
such by the EU, others are operating independent control/eradication programmes designed
speciﬁcally for their own situations and these may be submitted to the EU for recognition.
There are a number of licensed BVD vaccines available and even without vaccination most
animals are subclinically infected, thus there is, as such, no welfare concern impacting large
numbers of animals. The disease has existed and currently exists apparently without such
animal welfare impacts on large numbers of animals and trade has been freely allowed without
any controls, unless disease freedom or a control programme has been recognised by the EU
for individual MSs, without any issue.
3.3.2. Outcome of the assessment of criteria in Annex IV for bovine viral
diarrhoea for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 13–17. According to the
assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the
outcome is ‘Yes’. With respect to different type of impact where the assessment is divided into current
and potential impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’
and, in case of no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for BVD for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 22.
Table 21: Outcome of the expert judgement related to criterion 5(b)(PI) of Article 9
Question Final outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare,
by causing suffering of large numbers of animals
NC 92 8 0
NC: non-consensus; number of judges: 13.
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According to the assessment here performed, BVD complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BVD complies with criterion 2.3, but not with 1
and 2.2 and this assessment is inconclusive on compliance with criteria 2.1 and 2.4. To be
eligible for category A, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and BVD complies with criterion 4, but not with criteria 3, 5a, 5c and
5d and this assessment is inconclusive on compliance with criterion 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BVD complies with criteria 1 and 2.3, but not
with 2.2 and this assessment is inconclusive on compliance with criteria 2.1 and 2.4. To be
eligible for category B, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and BVD complies with criterion 4, but not with criteria 3, 5a, 5c and
5d and this assessment is inconclusive on compliance with criterion 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BVD complies with criteria 1, 2.2 and 2.3 and
this assessment is inconclusive on compliance with criteria 2.1 and 2.4. To be eligible for
category C, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and BVD does not comply with criteria 3, 4, 5a, 5c and 5d and this assessment
is inconclusive on compliance with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which BVD
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to
animal health, animal welfare, human health, the economy, society or the environment. The
latter is applicable if a disease fulﬁls the criteria as in Article 5, with which BVD complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
BVD. The Article 8(3) criteria are about animal species to be listed, as it reads below:
Table 22: Outcome of the assessment of criteria in Annex IV for bovine viral diarrhoea for the
purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.2 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for BVD according to the criteria of
Article 8(3) of the AHL are as displayed in Table 23.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, bovine viral diarrhoea complies with all criteria of
the ﬁrst set and with two criteria of the second set and therefore can be considered eligible to
be listed for Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
Table 23: Main animal species to be listed for bovine viral diarrhoea according to criteria of Article
8 (source: data reported in Section 3.1.1.1)
Order Family Genus/Species
Susceptible Artiodactyla Bovidae American bison (Bison bison), cattle (Bos taurus), chamois
(Rupicapra pyrenaica pyrenaica), eland (Taurotragus oryx),
mountain goat (Oreamnos americanus), nilgai (Boselaphus
tragocamelus), sheep (Ovis spp.), goat (Capra spp.), springbok
(Antidorcas marsupialis), topi (Damaliscus lunatus jimela), tsessebe
(Damaliscus lunatus), waterbuck (Kobus ellipsiprymnus), wildebeest
(Connochaetes taurinus)
Cervidae Axis deer (Axis axis), barasingha (Cervus duvaucelii), water deer
(Hydropotes inermis), mule deer (Odocoileus hemionus), red deer
(Cervus elaphus), roe deer (Capreolus capreolus), sika deer (Cervus
nippon), white-tailed deer (Odocoileus virginianus)
Girafﬁdae Giraffe (Giraffa camelopardalis)
Antilocapridae Pronghorn (Antilocapra americana)
Camelidae Alpaca (Vicugna pacos), dromedary (Camelus dromedarius), llama
(Lama glama), vicu~na (Vicugna vicugna)
Suidae Domestic pig and wild boar (Sus scrofa)
Traguilidae Mouse-deer (Tragulus javanicus)
Lagomorpha Leporidae Rabbit (Oryctolagus cuniculus), European hare (Lepus europaeus)
Rodentia Muridae Mouse (not speciﬁed)
Reservoir Artiodactyla Bovidae Cattle (Bos taurus), sheep (Ovis aries), goat (Capra aegrarus)
Lagomorpha Leporidae Rabbit (Oryctolagus cuniculus), European hare (Lepus europaeus)
(suspected role)
Vectors None
2 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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• According to the assessment here performed, bovine viral diarrhoea meets the criteria as in
Sections 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control
rules referred to in points (d) and (e) of Article 9(1) of the AHL. According to the assessment
here performed, it is inconclusive whether bovine viral diarrhoea complies with the criteria as in
Section 3 of Annex IV of the AHL, for the application of the disease prevention and control rules
referred to in point (c) of Article 9(1) of the AHL. Compliance of bovine viral diarrhoea with the
criteria as in Section 3 is dependent on a decision on criteria 2.1, 2.4 and 5(b).
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for bovine viral diarrhoea according to Article 8(3) of the AHL are, as reported in
Table 23 in Section 3.4 of the present document, several species of the families Bovidae,
Cervidae and Camelidae, giraffe, pronghorn, mouse-deer, pig, rabbit, European hare, and some
mouse species as susceptible species; cattle, sheep, rabbit and European hare can be
considered to be listed as reservoir species.
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AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
BCR beneﬁt/cost ratio
BHV Bovine herpes virus
BVD Bovine viral diarrhoea
BVDV Bovine viral diarrhoea virus
CDC Centers for Disease Control and Prevention
CFSPH Centre for Food Security and Public Health
CITES Convention on International Trade in Endangered Species of Wild Fauna and Flora
CI conﬁdence intervals
ELISA enzyme-linked immunosorbent assay
ICBA Individual and Collective Behavioural Aggregation
IHC immunohistochemistry
IUCN International Union for Conservation of Nature
IV intravenous
MDA Maternally derived antibodies
MS Member State
NA nucleic acid
OIE World Organisation for Animal Health
ON oronasal
PBS phosphate buffered saline
PCR polymerase chain reaction
PI persistently infected
RT-PCR reverse transcription polymerase chain reaction
TI transiently infected
TMR total mixed ration
ToR Terms of Reference
VN virus neutralisation
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